These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17266581)

  • 1. Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs.
    Xiao L; Rasouli P; Ruden DM
    Curr Med Chem; 2007; 14(2):223-32. PubMed ID: 17266581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
    Lu X; Xiao L; Wang L; Ruden DM
    Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
    Bagatell R; Beliakoff J; David CL; Marron MT; Whitesell L
    Int J Cancer; 2005 Jan; 113(2):179-88. PubMed ID: 15455381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
    Xiao L; Lu X; Ruden DM
    Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
    Hwang M; Moretti L; Lu B
    Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.